New Hope for Chronic Lung Disease Patients
Posted on: Monday, 19 May 2008, 15:00 CDT
U.S. medical scientists have found a new type of immune response that might lead to improved treatment of people with chronic inflammatory lung disease.
Researchers at Washington University School of Medicine in St. Louis said the immune response is activated in patients with severe asthma and COPD -- chronic obstructive pulmonary disease.
We've cracked the first part of the molecular code that links a viral infection to the later development of chronic inflammatory diseases like asthma and COPD, said senior author Dr. Michael Holtzman, a professor of medicine and a pulmonary specialist at Barnes-Jewish Hospital. With this information, we can more precisely diagnose and monitor these types of diseases and then better target our treatment to specific abnormalities. That's a big step forward from simply monitoring breathing status.
The findings are reported in the online edition of the journal Nature Medicine.
Source: United Press International
Related Articles
- Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market
- Alternative Medicine Use Increasing For Patients With Chronic Rhinosinusitis
- MEDai Enhances Chronic Care Management with Real-Time, Evidence-Based Medicine Guideline Analysis
- Special Report on Nonsurgical Spinal Decompression to Treat Chronic Low Back Pain Now in the January Issue of Pain Medicine News
- Efficacy of Selected Complementary and Alternative Medicine Interventions for Chronic Pain
- Study: Diabetes Drug Use Spikes in Girls
- New, Once Daily Medicine Available for Treatment for Moderate to Moderately Severe Chronic Pain in Adults
- Science News Cover Story Highlights Hemispherx Biopharma in New Insights Confronting Chronic Fatigue Syndrome; Promising Experimental Medicine is Designated First Specific Drug Candidate for CFS
- The New England Journal of Medicine Reports BARACLUDE(TM) (Entecavir) Demonstrated Benefits Over Lamivudine In Treating Chronically Infected Hepatitis B Patients at 48 Weeks
- New England Journal of Medicine Article Supports PEGASYS(R) As a First-Line Therapy in Chronic Hepatitis B
 |
 |
User Comments (0)
RSS Feeds